


# Gastroesophageal Reflux Disease and Severe Asthma

**Christopher Vélez, MD**

Program Director, Advanced Fellowship in  
Neurogastroenterology and Motility Disorders;  
Massachusetts General Hospital Center for Neurointestinal Health;  
Division of Gastroenterology, Hepatology, and Endoscopy;  
Mass General Brigham Department of Medicine;  
Harvard Medical School.





# Disclosures and Conflicts of Interest



- I have received funding from the following sources:
  - Cystic Fibrosis Foundation
  - Ironwood
  - Ardelyx – investigator initiated trial of tenapanor in CF-related constipation
  - American College of Gastroenterology
  - Consultant Eli Lilly
  - Internal MGH diversity, equity, and inclusion funding initiatives



# Outline

- **Case introduction**
- Why is there an interloping gastroenterologist?
- The relationship between GERD and asthma
- How I approach GERD evaluation/refractory GERD
- Case wrap-up and clinical pearls



# Case

- 54-year-old woman with a history of asthma with potential COPD overlap syndrome, complicated by recurrent exacerbations and hospitalizations (including ICU stays) presents to establish care with me in my community gastroenterology practice.
- She has a history of malformation of her subclavian artery, which compresses her esophagus and contributes to recurrent aspiration and pneumonia, never repaired (because of heavier smoking at the time of first evaluation).
- Her asthma/COPD exacerbations are quite frequent despite the use of triple therapy which includes inhaled steroids/long-acting beta agonists, long-acting muscarinic antagonist, as well as montelukast, with frequent need for steroids.
  - Possibly due to repeated insults from aspiration?




# Case

- She was initiated on dupilumab. There was an initial period where dupilumab seemed to be making a difference.
  - There was another period of worsening symptoms and need for prednisone, leading us to transition to another agent, benralizumab, which has also not made a significant difference.
- I have been tasked to examine her since she has heartburn and regurgitation.
  - Also to determine if there is a component of her symptoms that could be related to GERD.
- Of note, body mass index is 35 kg/m<sup>2</sup>, likely driven in part due to repetitive need for systemic glucocorticoids.
- Endoscopy done 10-years prior without concerning pathology.
- Patient is on omeprazole 40 mg twice daily and famotidine 40 mg nightly.
  - Omeprazole does not control typical GERD symptoms.
  - What is aspiration vs GERD?



## Case

- As you listen to this talk, I would like for you to think of the following points:
  - What, if any additional gastroenterology testing is needed?
  - Is this severe asthma related to GERD, if she is maximally suppressed?



# Outline



- Case introduction
- **Why is there an interloping gastroenterologist?**
- The relationship between GERD and asthma
- How I approach GERD evaluation/refractory GERD
- Case wrap-up and clinical pearls



# Gastroenterologists and Pulmonologists



- Embryologically kindred organ systems.
- Both organs are a set of tubes.
- Similar disease processes (vascular, inflammatory, malignant, infectious) plague both organ tracts.
- Specialists within the specialty focus on procedural care, critical illness, preventive care, and addressing health inequity that can exist among different communities.





# Thinking about a combined aerodigestive system

[Intro to CF](#)[Managing CF](#)[Research and Clinical Trials](#)[Support](#)[Community Blog](#)[News](#)[Search](#)[Local Chapter](#)[español](#)[GET INVOLVED](#)[DONATE](#)


## Developing Innovative Gastroenterology Specialty Training (DIGEST) Program

The Cystic Fibrosis Foundation recognizes the growing demand for physicians who are trained to address the unique gastroenterological needs of people with cystic fibrosis and the need for a greater focus on gastrointestinal (GI) issues in the [clinical research](#) enterprise.

2 min read




## Manifestations of Cystic Fibrosis





# Heartburn and reflux: GERD



- Increased GER occurs when there is an imbalance between protective factors and aggravating factors
- Protective factors
  - Esophageal motility
  - Salivary bicarbonate
  - **Lower esophageal sphincter**
  - **Diaphragmatic crura**
  - **Gastric cardia**/ angle of His
- Aggravating factors
  - Increased intra-abdominal pressure
  - Excessive acid exposure
  - Impaired anti-reflux barriers (hiatal hernia, excessive transient lower esophageal sphincter relaxation)



# GI-related aspiration (GRASP)

- Lung transplant outcomes are worse than all other solid organ transplant
- "Reflux" has been used as a short-hand for movement of foregut contents from the upper GI tract into the respiratory tree
  - Bile salts found in bronchoalveolar lavage
- Cystic Fibrosis Foundation has made a priority to study how GRASP impacts advanced lung disease and lung transplant survival
  - Standardization of motility testing protocol – is it needed? Does it change management? What tests should be used? Esophageal manometry vs wireless pH testing vs pH-mucosal intraluminal impedance, gastric emptying scan.
  - Should protocolized motility testing be offered irrespective of symptoms? Silent reflux? Lack of correlation between gastric emptying and gastroparesis symptoms?
  - Should motility testing be symptom-based?




## **GRASPing for answers: The shortfalls of our current understanding of the effects of GI-related aspiration on the lungs in CF (GRASP-CF)<sup>\*</sup>**

Vélez C, Neuringer I, King J. GRASPing for answers: The shortfalls of our current understanding of the effects of GI-related aspiration on the lungs in CF (GRASP-CF). *J Cyst Fibros*. 2024 Sep 27:S1569-1993(24)01779-X. doi: 10.1016/j.jcf.2024.09.014. Epub ahead of print. PMID: 39341689.




# GI-related aspiration (GRASP)





# GI-related aspiration (GRASP)



OFFICIAL JOURNAL OF THE AMERICAN COLLEGE OF GASTROENTEROLOGY | ACG



# Outline

- Case introduction
- Why is there an interloping gastroenterologist?
- **The relationship between GERD and asthma**
- How I approach GERD evaluation/refractory GERD
- Case wrap-up and clinical pearls




# Relationship between GERD and asthma




- Asthma is heterogeneous, with incompletely characterized phenotypes.
- Multiple comorbidities (GERD, obstructive sleep apnea, obesity) are often present at higher incidence in those with asthma compared to those without asthma.
  - Are there shared pathophysiologic/inflammatory pathways?
- It has been estimated that GERD can occur in 30% and 80% of patients with asthma.
- Yet, the impact of acid suppression on asthma outcomes is unclear.
- Leads to a great degree of patient uncertainty and physician/patient frustration in more severe asthma cases.



# Relationship between GERD and asthma



**Figure 2** Organisation of articles retrieved from literature searches. GORD, gastro-oesophageal reflux disease.





# Relationship between GERD and asthma



## Effects of Asymptomatic Proximal and Distal Gastroesophageal Reflux on Asthma Severity

Emily DiMango<sup>1</sup>, Janet T. Holbrook<sup>2</sup>, Erin Simpson<sup>1</sup>, Joan Reibman<sup>3</sup>, Joel Richter<sup>4</sup>, Surinder Narula<sup>1</sup>, Nancy Prusakowski<sup>2</sup>, John G. Mastronarde<sup>5</sup>, and Robert A. Wise<sup>2,6</sup>, for the American Lung Association Asthma Clinical Research Centers\*

<sup>1</sup>Columbia University, College of Physicians and Surgeons, New York, New York; <sup>2</sup>Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; <sup>3</sup>New York University School of Medicine, New York, New York; <sup>4</sup>Temple University School of Medicine, Philadelphia, Pennsylvania; <sup>5</sup>The Ohio State University Medical College, Columbus, Ohio; and <sup>6</sup>Johns Hopkins University School of Medicine, Baltimore, Maryland

- Rationale: Silent gastroesophageal reflux (GER) is common in patients with asthma, but it is unclear whether GER is associated with worse asthma symptoms or reduced lung function.
- Objectives: To determine in patients with poorly controlled asthma, whether proximal or distal esophageal reflux is associated with asthma severity, symptoms, physiology, or functional status.
- Methods: Baseline asthma characteristics were measured in patients with asthma enrolled in a multicenter trial assessing the effectiveness of esomeprazole on asthma control.
  - All participants underwent 24-hour esophageal pH probe monitoring.
  - Lung function, methacholine responsiveness, asthma symptoms, and quality-of-life scores were compared in subjects with and without GER.



# Relationship between GERD and asthma



TABLE 2. BASELINE ASTHMA CHARACTERISTICS FOR SUBJECTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX

| Asthma characteristics   | pH Probe Result             |  | P Value* |
|--|-----------------------------|--|----------|
|  | Distal or Proximal Positive | Distal Negative and Proximal Negative or Missing |          |
| N (%)  | 160 (53)                    | 144 (47)   |          |
| Mean age of asthma onset, yr ± SD  | 16 ± 17                     | 17 ± 17  | 0.14     |
| Use of inhaled short-acting β-agonist (MDI/Neb) ≥ 2 times/wk, % of group | 81                          | 78   | 0.55     |
| ≥2 Unscheduled health care visit in past yr, %                           | 64                          | 57   | 0.54     |
| ACQ ≥ 1.5, %   | 92                          | 91   | 0.78     |
| Oral corticosteroids for asthma in past yr, %                            | 56                          | 43   | 0.03     |
| Night awakenings due to asthma in past 2 wk, %                           | 18                          | 10   | 0.08     |
| Daily use of ICS, %  | 100                         | 100  |          |
| Daily dose of ICS, μg  | 663 ± 23.4                  | 647 ± 21.7                                       | 0.31     |
| Mean ACS (↓) (score range: 0–6) ± SD                                     | 1.9 ± 0.9                   | 1.8 ± 0.8  | 0.25     |
| Mean ASUI (↑) (score range: 0–1) ± SD                                    | 0.73 ± 0.18                 | 0.77 ± 0.15                                      | 0.08     |
| Mean AQL (↑) (score range: 1–7) ± SD                                     | 4.4 ± 1.3                   | 4.8 ± 1.2  | 0.01     |
| SF-36 quality of life (↑) (score range: 0–100), N                        | 160                         | 143  |          |
| Mean physical score ± SD   | 41 ± 10                     | 43 ± 10  | 0.06     |
| Mean emotional score ± SD  | 48 ± 11                     | 49 ± 11  | 0.56     |
| Mean pulmonary function measures, N                                      | 160                         | 144  |          |
| Pre-BD FEV <sub>1</sub> , % predicted ± SD <sup>†</sup>                  | 76 ± 15                     | 77 ± 14  | 0.84     |
| Pre-BD FVC, % predicted ± SD <sup>†</sup>                                | 87 ± 15                     | 88 ± 13  | 0.56     |
| FEV <sub>1</sub> , % change post-BD ± SD                                 | 10 ± 9                      | 11 ± 11  | 0.15     |
| FVC, % change post-BD ± SD   | 5 ± 8                       | 6 ± 8  | 0.37     |
| Peak expiratory flow rate (% predicted ± SD)                             | 79 ± 18                     | 80 ± 17  | 0.40     |
| Methacholine contraindicated (% of group)                                | 60                          | 55   | 0.39     |
| PC <sub>20</sub> , mg/ml, N, mean ± SD                                   | 61, 3.4 ± 4.0               | 64, 4.3 ± 5.1                                    | 0.94     |

- Results: Of 304 participants with probe recordings, 53% had reflux.
  - Of 242 participants with recordings of proximal pH, 38% had proximal reflux.
  - There was no difference in need for short-acting bronchodilators, nocturnal awakenings, dose of inhaled corticosteroid, use of long-acting b-agonists, lung function, or methacholine reactivity between individuals with and without proximal or distal GER.
  - Participants with GER reported more use of oral corticosteroids and had worse asthma quality of life and subjects with proximal GER had significantly worse asthma quality of life and health-related quality of life compared with participants without GER.
- Conclusions: Asymptomatic GER is not associated with distinguishing asthma symptoms or lower lung function in individuals with suboptimal asthma control who are using inhaled corticosteroids.
  - Patients with proximal reflux report significantly worse asthma and health-related quality of life despite lack of physiologic impairment or increase in asthma symptoms.



# Relationship between GERD and asthma



*The* NEW ENGLAND  
JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

APRIL 9, 2009

VOL. 360 NO. 15

## Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma

The American Lung Association Asthma Clinical Research Centers\*

### ■ Methods

- 402 people with asthma with inadequate asthma control despite inhaled corticosteroids and absent or minimal GER symptoms were randomly assigned to either esomeprazole 40mg b.i.d. or matching placebo in a parallel-group double-masked clinical trial.
- Participants were followed for 24 weeks with daily asthma diaries, every 4-week spirometry, and asthma symptom questionnaires.
- Participants were classified with respect to GER status with ambulatory pH probe monitoring.
- The primary outcome was the rate of episodes of poor asthma control (EPACs) based on asthma diaries.



# Relationship between GERD and asthma




**Table 3. Episodes of Poor Asthma Control and Component Events.\***

| Variable   | Placebo<br>(N=193) | Esomeprazole<br>(N=200) | Incidence-<br>Rate Ratio,<br>Esomeprazole<br>vs. Placebo<br>(95% CI) | P Value                      |  |
|--|--------------------|-------------------------|--|------------------------------|--|
|  |                    |                         |  | Esomeprazole<br>vs. Placebo† | Gastroesophageal-<br>Reflux Interaction‡ |
| <b>Asthma episodes, according to definition that did not include use of beta-agonists as a criterion</b> |                    |                         |  |                              |  |
| No. of events  | 201                | 224                     |  |                              |  |
| No. of events/person-yr  | 2.3                | 2.5                     | 1.1 (0.8–1.5)  | 0.66                         | 0.93                                     |
| Patients with ≥1 event (%)   | 42                 | 42                      |  |                              |  |
| <b>Exacerbation components</b>   |                    |                         |  |                              |  |
| <b>≥30% drop in peak expiratory flow on 2 consecutive days</b>   |                    |                         |  |                              |  |
| No. of events  | 141                | 180                     |  |                              |  |
| No. of events/person-yr  | 1.7                | 2.1                     | 1.2 (0.8–2.0)  | 0.35                         | 0.99                                     |
| Patients with ≥1 event (%)   | 26                 | 28                      |  |                              |  |
| <b>Urgent care visit</b>   |                    |                         |  |                              |  |
| No. of events  | 53                 | 51                      |  |                              |  |
| No. of events/person-yr  | 0.6                | 0.6                     | 0.9 (0.6–1.5)  | 0.79                         | 0.44                                     |
| Patients with ≥1 event (%)   | 17                 | 18                      |  |                              |  |
| <b>New use of oral corticosteroids</b>   |                    |                         |  |                              |  |
| No. of events  | 50                 | 48                      |  |                              |  |
| No. of events/person-yr  | 0.6                | 0.5                     | 0.9 (0.6–1.3)  | 0.62                         | 0.85                                     |
| Patients with ≥1 event (%)   | 24                 | 21                      |  |                              |  |

- Episodes of poor asthma control occurred with similar frequency in the placebo and esomeprazole treatment groups (2.3 vs 2.5 events/person-year, respectively, P=0.66).
- There was no treatment effect with respect to components of the EPACs, or secondary outcomes including pulmonary function, airways reactivity, asthma control, symptom scores, nocturnal awakenings, or quality of life.
- GER documented by pH probe studies in 40% of participants with absent or minimal symptoms did not identify a subgroup benefitting from PPI treatment.
- Conclusion—Despite a high prevalence of asymptomatic GER in patients with poorly controlled asthma, treatment with proton pump inhibitors does not improve control. Silent GER is not a likely cause of poorly controlled asthma



# Relationship between GERD and asthma





 CHEST®



Volume 128, Issue 3, September 2005, Pages 1128-1135

Clinical Investigations

## Effects of 24 Weeks of Lansoprazole Therapy on Asthma Symptoms, Exacerbations, Quality of Life, and Pulmonary Function in Adult Asthmatic Patients With Acid Reflux Symptoms

Littner Michael R. MD <sup>a</sup>  , Leung Felix W. MD <sup>a</sup>, Ballard E. David II MD <sup>b</sup>, Huang Bidan PhD <sup>c</sup>, Samra Nina K. MS <sup>d</sup>

- **Background:** Difficult-to-control asthma has been associated with gastroesophageal acid reflux. Acid-suppressive treatment has been inconsistent in improving asthma control.
- **Objective:** To determine whether a proton-pump inhibitor improves asthma control in adult asthmatic patients with acid reflux symptoms.
- **Design:** Multicenter, double-blind, randomized, placebo-controlled trial.
- **Setting:** Twenty-nine private practices and 3 academic practices in the United States.
- **Patients:** Two hundred seven patients receiving usual asthma care including an inhaled corticosteroid (ICS). Patients had acid reflux symptoms and moderate-to-severe persistent asthma.
- **Intervention:** Lansoprazole, 30 mg bid, or placebo, bid, for 24 weeks.
- **Measurements:** The primary outcome measure was daily asthma symptoms by diary. Secondary asthma outcomes included rescue albuterol use, daily morning and evening peak expiratory flow, FEV1, FVC, asthma quality of life with standardized activities (AQLQS) questionnaire score, investigator-assessed symptoms, exacerbations, and oral corticosteroid-treated exacerbations.




# Relationship between GERD and asthma



## Results:

- Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo.
- Fewer patients receiving lansoprazole (8.1% vs 20.4%, respectively;  $p = 0.017$ ) had exacerbations and oral corticosteroid-treated (ie, moderate-to-severe) exacerbations (4% vs 13.9%, respectively;  $p = 0.016$ ) of asthma.
- A post hoc subgroup analysis revealed that fewer patients receiving one or more long-term asthma-control medications in addition to an ICS experienced exacerbations (6.5% vs 24.6%, respectively;  $p = 0.016$ ) and moderate-to-severe exacerbations (2.2% vs 17.5%, respectively;  $p = 0.021$ ) with lansoprazole therapy.



## Conclusion:

- Treatment with 30 mg of lansoprazole bid for 24 weeks did not improve asthma symptoms or pulmonary function or reduce albuterol use.
- However, this dose significantly reduced asthma exacerbations and improved asthma quality of life, particularly in those patients receiving more than one asthma-control medication.



# Relationship between GERD and asthma



- Possible future research directions:
  - Efficacy of GERD treatment in patients with asthma with manometry- and pH-proven pathologic gastro-esophageal reflux disease with or without traditional GERD symptoms.
  - Examining whether a distinction needs to be drawn between proximal vs distal esophageal reflux.
  - Examining asthma outcomes as it relates to medical, endoluminal, and surgical GERD treatments.



# Outline

- Case introduction
- Why is there an interloping gastroenterologist?
- The relationship between GERD and asthma
- **How I approach GERD evaluation/refractory GERD**
- Case wrap-up and clinical pearls



# TL, DR: Please do not rely on esophagrams to diagnose clinically significant reflux



CME

## ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease

Philip O. Katz, MD, MACG<sup>1</sup>, Kerry B. Dunbar, MD, PhD<sup>2-3</sup>, Felice H. Schnoll-Sussman, MD, FACP<sup>1</sup>, Katarina B. Greer, MD, MS, FACP<sup>4</sup>, Rena Yadlapati, MD, MSHS<sup>5</sup> and Stuart Jon Spechler, MD, FACP<sup>6-7</sup>

---

- Barium radiographs should not be used solely as a diagnostic test for GERD.
- The presence of reflux on a barium esophagram or upper GI series has poor sensitivity and specificity for GERD when compared with pH testing.
- In one study, only about one-half of patients with abnormal reflux on a barium study were found to have abnormal pH monitoring.
- The finding of barium reflux above the thoracic inlet with or without provocative maneuvers (including the water siphon test) somewhat increases the sensitivity for reflux, but not sufficiently for barium esophagram to be recommended as a diagnostic test for GERD



# Testing for foregut conditions potentially impacting respiratory tree

| Disease   | Definition  | Symptoms  | Diagnosis   | Treatment (selected)  |
|---|---|---|---|---|
| Gastro-esophageal reflux disease (GERD), possibly with laryngopharyngeal reflux (LPR) | <p><u>Endoscopic findings:</u> Peptic stricture, erosive esophagitis, Barrett's esophagus</p> <p><u>Ambulatory reflux monitoring:</u></p> <ul style="list-style-type: none"> <li>Elevated acid exposure time in the esophagus</li> <li>Excessive reflux episodes</li> <li>Nascent consensus as to LPR definitions and diagnosis, but not widely employed</li> </ul> | <p><u>Esophageal:</u> heartburn, regurgitation</p> <p><u>Extra-esophageal:</u> cough, sinusitis, voice change, exacerbation of chronic lung disease</p> | <p><u>GERD symptom improvement</u></p> <ul style="list-style-type: none"> <li>Favorable symptom response to acid suppression</li> </ul> <p><u>Ambulatory reflux monitoring</u></p> <ul style="list-style-type: none"> <li>Elevated acid exposure time in the esophagus (<i>Conclusive:</i> &gt;6 % over 24-hours; <i>Inconclusive:</i> 4–6 % over 24-hours);</li> <li>Excessive reflux episodes (<i>Conclusive:</i> &gt;80 episodes over 24-hour period; <i>Inconclusive:</i> 40–80 episodes over 24-hour period)</li> </ul> <p><u>Esophagogastroduodenoscopy (EGD) demonstrating:</u></p> <ul style="list-style-type: none"> <li>Barrett's esophagus – esophageal intestinal metaplasia,</li> <li>Erosive esophagitis – LA Grades B, C, and D</li> <li>Peptic stricture</li> </ul> | <p><u>Medical:</u></p> <ul style="list-style-type: none"> <li>Histamine 2 antagonism (famotidine)</li> <li>Proton pump inhibition</li> <li>Potassium competitive acid blockers (vonoprazan)</li> </ul> <p><u>Endoluminal:</u></p> <ul style="list-style-type: none"> <li>Transoral incisionless fundoplication</li> <li>Radiofrequency (Stretta)</li> </ul> <p><u>Surgical:</u></p> <ul style="list-style-type: none"> <li>Surgical fundoplication (e.g. Nissen, Toupet, Dor etc.)</li> </ul> |



# Testing for foregut conditions potentially impacting respiratory tree

## Gastroparesis (GP)

### Endoscopic findings:

Retained food/food bezoar

### Motility testing

- Gastric emptying scan/scintigraphy (GES)
- Wireless motility capsule (WMC)
- Gastric emptying breath test (GEBT)

### Motor symptoms:

Nausea, vomiting, early satiety

### Sensory symptoms:

Nausea, abdominal pain

### Motor abnormalities:

- GES: >10 % solid food retained at 4-hours
- WMC: Failure of capsule to progress in less than 5-hours
- GEBT: Variation of carbon isotopes over time

### Sensory abnormalities:

- Symptom reporting
- Patient reported outcome measures

### Medical:

- Macrolide antibiotics (azithromycin, erythromycin)
- Dopaminergic (metoclopramide, domperidone\*)
- Serotonergic (prucalopride\*)


### Endoluminal:

- Per oral pyloromyotomy (POP)
- Botulinum toxin injection (pylorus)

### Surgical:


- Gastric stimulator (Enterra)
- Surgical pyloroplasty

\*depending on jurisdiction



# Esophageal motility testing: Chicago

CC v. 4.0







# Esophageal manometry output

## Chicago Classification:

Achalasia




EGJ Outflow Obstruction




Major Disorders of Peristalsis:


*DES*



*Jackhammer*




*Absent peristalsis*




Minor Disorders of Peristalsis:


*IEM*



*Fragmented peristalsis*




Normal






# Absent GERD by AET, reflux # (MII-pH)






# Definitive GERD by AET, reflux # (MII-pH)






# Definitive GERD by AET, reflux # (Bravo)







# Lyon Consensus: Reflux





# Lyon Consensus: Reflux





# Lyon Consensus: Reflux

|   | UNPROVEN GERD<br>ENDOSCOPY, WIRELESS pH STUDY, 24 HOUR pH OR pH IMPEDANCE, HRM<br><i>off therapy</i> |   |  | PROVEN GERD<br>ENDOSCOPY,<br>24 HOUR pH IMPEDANCE<br><i>on therapy</i>                    |
|---|--|---|--|---|
|   | ENDOSCOPY  | pH or pH-IMPEDANCE  | HRM  | ENDOSCOPY<br>pH-IMPEDANCE   |
| CONCLUSIVE EVIDENCE FOR PATHOLOGIC REFLUX | LA grades B, C&D esophagitis<br>Biopsy proven Barrett's mucosa<br>Peptic esophageal stricture        | AET>6% on 24 hour studies<br>AET>6% on ≥2 days on wireless studies  |  | LA grades B, C&D esophagitis<br>Peptic esophageal stricture<br>AET>4%, reflux episodes>80 |
| BORDERLINE OR INCONCLUSIVE EVIDENCE       | LA grade A esophagitis   | AET 4-6% on 24 hour studies<br>AET 4-6% on ≥2 days on wireless studies<br>Total reflux episodes 40-80/day |  | LA grade A esophagitis<br>AET 1-4%<br>Total reflux episodes 40-80/day<br>MNBI 1500-2500 Ω |
| ADJUNCTIVE OR SUPPORTIVE EVIDENCE*        | Hiatus hernia<br>Histopathologic scoring systems<br>Electron microscopy of biopsies                  | Reflux-symptom association<br>Total reflux episodes >80/day<br>MNBI<1500 Ω                                | Hypotensive EGJ<br>Hiatus hernia<br>IEM/absent contractility | Hiatus hernia<br>MNBI <1500 Ω<br>Reflux symptom association                               |
| EVIDENCE AGAINST PATHOLOGIC REFLUX        |  | AET<4% each day of study**<br>Total reflux episodes<40/day<br>MNBI>2500 Ω                                 |  | AET<1%<br>Total reflux episodes <40/day<br>MNBI>2500 Ω                                    |



# Outline

- Case introduction
- Why is there an interloping gastroenterologist?
- The relationship between GERD and asthma
- How I approach GERD evaluation/refractory GERD
- **Case wrap-up and clinical pearls**



## Case wrap-up



- She is on the maximum daily dose of omeprazole, among the more potent proton pump inhibitors.
  - Consider switch to rabeprazole?
  - Consider potassium competitive acid blocker (vonoprazan)?
- Fortunately, with no recent endoscopy, the decision to exclude erosive esophagitis is an easy one (as the next clinical step).
  - Could pair this with a wireless 96-hour BRAVO test (off of PPI since we do not have established GERD).
  - Or, could consider 2 pH probe catheter-based multichannel intraluminal impedance 24-hour test.
- Emphasis on weight loss, as this contributes to refluxate.
- Readdressing possible surgical intervention of aberrant subclavian artery.



## Clinical pearls: Severe asthma and GERD



- While asthma and GERD are frequently comorbid conditions, and causality to some degree is likely, we cannot predict well which patients with severe asthma will improve with more aggressive GERD treatment.
- In refractory/severe asthma cases, it is reasonable to pursue ambulatory reflux monitoring (ideally off acid suppression) to determine if there is intervenable GI disease.
- Know the limitations of the different diagnostic modalities and treatments, prior to invoking GERD in the management of patients with severe asthma.
  - Do not rely on esophagrams.